Tweet
Published 25 May 2023
DOI https://doi.org/10.1038/s41421-023-00556-w
Zhou, B., Wang, H., Cheng, L. et al.
Dear Editor,
Human monkeypox has been a rare zoonotic disease caused by the monkeypox virus (MPXV) infection which is mainly reported in West and Central Africa in the past1. However, since the first confirmed case was found in the United Kingdom on May 7, 2022, there were over 87,000 confirmed cases worldwide until April, 2023 (https://worldhealthorg.shinyapps.io/mpx_global/). Human monkeypox seems to have become a multi-country outbreak disease and it was declared a Public Health Emergency of International Concern by the World Health Organization on July 23, 2022.
MPXV belongs to a member of Orthopoxvirus (OPXV) genus and is close to the infamous smallpox virus, yet causing relatively milder illness in humans2. MPXV infection causes 3.6% and 10.6% fatality in the West African clade and the Central African clade, respectively3,4. MPXV has a broad host range and many mammalian cells are susceptible to its infection5. Smallpox vaccines are hopeful to fight against MPXV, which could provide about 85% protection6, and could induce long-term humoral immunity for up to 75 years7,8. In this study, we evaluated the cross-recognization of this preexisting humoral immune response to MPXV including circulating polyclonal antibodies (pAbs) and memory B cells (MBCs), and revealed the key features of two isolated monoclonal antibodies (mAbs).
OPXV contains two kinds of virions, mature virion (MV) and enveloped virion (EV), carrying different surface antigens9. Taking vaccinia virus (VACV) as an example, several neutralizing antibody targets have been identified, such as L1, H3, A13, A17, and A27, and etc. on the MV and B5 and A33 on the EV3. We selected four representative homologous proteins of MPXV (H3 (equivalent to H3 in VACV) and A29 (A27 in VACV) on the MV; B6 (B5 in VACV) and A35 (A33 in VACV) on the EV)10, to detect the long-lasting antibody cross-binding to the MPXV in humans. ...
https://www.nature.com/articles/s414...00556-w#citeas
DOI https://doi.org/10.1038/s41421-023-00556-w
Zhou, B., Wang, H., Cheng, L. et al.
Dear Editor,
Human monkeypox has been a rare zoonotic disease caused by the monkeypox virus (MPXV) infection which is mainly reported in West and Central Africa in the past1. However, since the first confirmed case was found in the United Kingdom on May 7, 2022, there were over 87,000 confirmed cases worldwide until April, 2023 (https://worldhealthorg.shinyapps.io/mpx_global/). Human monkeypox seems to have become a multi-country outbreak disease and it was declared a Public Health Emergency of International Concern by the World Health Organization on July 23, 2022.
MPXV belongs to a member of Orthopoxvirus (OPXV) genus and is close to the infamous smallpox virus, yet causing relatively milder illness in humans2. MPXV infection causes 3.6% and 10.6% fatality in the West African clade and the Central African clade, respectively3,4. MPXV has a broad host range and many mammalian cells are susceptible to its infection5. Smallpox vaccines are hopeful to fight against MPXV, which could provide about 85% protection6, and could induce long-term humoral immunity for up to 75 years7,8. In this study, we evaluated the cross-recognization of this preexisting humoral immune response to MPXV including circulating polyclonal antibodies (pAbs) and memory B cells (MBCs), and revealed the key features of two isolated monoclonal antibodies (mAbs).
OPXV contains two kinds of virions, mature virion (MV) and enveloped virion (EV), carrying different surface antigens9. Taking vaccinia virus (VACV) as an example, several neutralizing antibody targets have been identified, such as L1, H3, A13, A17, and A27, and etc. on the MV and B5 and A33 on the EV3. We selected four representative homologous proteins of MPXV (H3 (equivalent to H3 in VACV) and A29 (A27 in VACV) on the MV; B6 (B5 in VACV) and A35 (A33 in VACV) on the EV)10, to detect the long-lasting antibody cross-binding to the MPXV in humans. ...
https://www.nature.com/articles/s414...00556-w#citeas